Moleculin Biotech Inc. (NASDAQ: MBRX)
$4.39
+0.1400 ( +3.29% ) 1.0K
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Market Data
Open
$4.39
Previous close
$4.25
Volume
1.0K
Market cap
$9.62M
Day range
$4.12 - $4.30
52 week range
$3.22 - $15.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 38 | Mar 25, 2024 |
8-k | 8K-related | 16 | Mar 22, 2024 |
10-k | Annual reports | 70 | Mar 22, 2024 |
8-k | 8K-related | 17 | Mar 20, 2024 |
8-k | 8K-related | 18 | Mar 19, 2024 |
8-k | 8K-related | 23 | Feb 29, 2024 |
8-k | 8K-related | 21 | Feb 22, 2024 |
8-k | 8K-related | 20 | Feb 15, 2024 |
8-k | 8K-related | 16 | Feb 14, 2024 |
8-k | 8K-related | 39 | Feb 14, 2024 |